The treatment of the hepatitis C virus has progressed well following the invention of the new direct acting antiviral. Nucleotide polymerase inhibitors come from a class of new medications considered to be more effective, well tolerated and safe as part of an antiviral regimen. Sofosbuvir is the first drug in this class of the new medication that has proved to be more active for medical use, supported by the results from the extensive phase III and phase II medical trials. The nucleotide polymerase inhibitors medication is used as a part of an interferon-free hepatitis C virus treatment regimen. The chronic hepatitis C virus infection is so ubiquitous and from research, it shows that about 180 million people globally and more than 3.2 million in the US are affected by it. Whilst ribavirin and peginterferon continue to be utilized, the curative landscape for patients with genotype 1 has presently changed to have one of the two protease inhibitors: telaprevir and boceprevir. Despite this, active therapies for chronic hepatitis C virus have all the genotypes representing a great unsolved urge. Nucleotide polymerase inhibitors are analogs of the natural substrates and are considered to bind the active site of the NS5B and let go of viral RNA chain generation. It also provides a great genetic barrier necessary for resistance and is so active in all the genotypes. Nucleotide polymerase inhibitors like sofosbuvir (GS-7977) indicate high antiviral activities that, together with their great genetic obstacle to a resistance, show that they are ideal backbone entrants for all-oral combination therapies. Many trials are being carried on to define further the potential of all-oral regimens with sofosbuvir (GS-7977). Topical interim analyzes show that several patients treated with only two direct-acting antiviral agents’ undergo viral breakthrough, which can be expressively minimized by the inclusion of ribavirin without pegylated interferon _.
Nucleotide Polymerase Inhibitors Drugs
Some of the drugs of nucleotide polymerase inhibitors include:
- Sofosbuvir (GS-7977)
- Pegylated interferon _.
Nucleotide Polymerase Inhibitors Uses
Nucleotide polymerase inhibitors are used in the treatment of hepatitis C virus. The standard cure for hepatitis C virus infection is the interferon. This interferon is administered intravenously and can have harsh side effects. Sofosbuvir is a type of oral nucleotide inhibitor used to inhibit the development of HCV polymerase, in interferon-free regimens and interferon-sparing for the cure of HCV infection.
The hepatitis C virus reproduction is instigated by the development of the replication complex. This is a structured of the hepatitis C viral proteins, cellular proteins, RNA and of relocated intracellular lipid membranes got from the endoplasmic reticulum.
Nucleotide Polymerase Inhibitors Side Effects
Some of the side effects of using Nucleotide polymerase inhibitors include:
- Higher fatigue
- Incidences of anaemia
Nucleotide Polymerase Inhibitors Interactions
Most nucleotide analogs indicated high levels of toxicity, leading to a cessation of their growth. Toxicity levels have varied and include cardiac, gastrointestinal, lymphopenia and hepatotoxicity. Equally, SOF has proved a great safety profile, both in medical tests and practices. The cumulative data show that the side effect profile of SOF replicates that of drugs with which it is directed.